Regeneron Pharmaceuticals (REGN)

Total return at 5 years: 5.6%/year = 5.1% appreciation + 0.5% dividend. The target price ($1,093) is ex-dividend; the $23 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $1,274 · Multiples $897) exceeds the market price ($852).

Today — fairly valued: at $852 trades ~5.0% below its value discounted to today (~$897); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($1,093) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$559.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($852) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-2.9%/year) than we project (7.5%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$3.3 bn of owner earnings in year 5 (vs ~$5.5 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM through June 2026 (revenue $15,534.7 million, +9.3% year over year). The base path starts at 9.5% in year 1 —within the observed band of year-over-year growth (1.0% to 9.3% over the last four closes) and supported by a concrete fact from the second-quarter 2026 earnings release: the development balance Sanofi owed Regeneron was fully repaid by the end of June 2026, which eliminates a recurring deduction from collaboration revenue starting in the third quarter onward— and decelerates smoothly to ~6.5% by year 5, reflecting the structural erosion of legacy EYLEA (−42% year over year from biosimilars) offset by EYLEA HD, Libtayo, and the growing Dupixent profit share. The 8-K dated Jul 30, 2026 (Item 2.02) does not carry formal full-year revenue or earnings-per-share guidance: only cost guidance (research and development, general expenses, product gross margin, cost of collaboration and manufacturing, capex, effective tax rate), declared here. The operating margin (EBIT/revenue) has been compressing from 38.9% (2022) to 24.7% (trailing twelve months) from the expansion of research and development, higher inventory reserves, and intangible amortization tied to Libtayo royalties to Sanofi; the base case projects a gradual recovery to 26% by year 5 as collaboration revenue —with higher incremental margin than product sales— gains relative weight, consistent with the guided 84%-85% non-GAAP product gross margin for 2026 (an improvement over the prior guidance of 83%-84%). Capex ($920.9 million over the trailing twelve months, 1.74× depreciation) reflects investment mode from the Tarrytown expansion and the Saratoga Springs construction; updated 2026 capex guidance is $1,030-1,100 million. Stock-based compensation is material against the flow (26.2% of trailing-twelve-month free cash flow, 6.4% of revenue, the method's TSLA case): the valuation metric (EV/NOPAT) automatically expenses it because GAAP operating income already includes it as an expense — no additional adjustment to `ocfMargin` is needed, which here is shown at the reported (gross) level solely as a cash-conversion reference, not as a valuation base. A single share path is modeled across the three scenarios (§6), with a net reduction of 2.4% per year funded entirely from real free cash flow (fcfLtm US$3.76 billion, buybackLtm US$3.30 billion — retention ~2%, consistent with a near-total payout, so no additional cash accumulates: `accumulateCash: false`). Starting cash (`cajaStart`) includes cash and equivalents plus current and non-current marketable securities as of Jun 30, 2026 (US$2.456+US$5.539+US$9.828 = US$17.823 million); debt (`deuda`) is only the fresh long-term debt from the 10-Q (US$1,986.6 million, 1.75% senior notes due 2030) — the XBRL current-debt tag is stale (72 months out of date, from 2020) and was discarded after confirming in the 10-K balance sheet that there is no separate current-debt line. ⚠️ The automatic §6 contrast abstains for Regeneron because the issuer does not publish an undimensioned shares-outstanding series —it has two classes—, so the rate is anchored in the only two available bases, which agree: the diluted weighted average falls from 108.6 million in the second quarter of 2025 to 106.0 in the same quarter of 2026 (−2.4%), and the US$3,299 million of buybacks over the trailing twelve months equal 3.65% of market value on a gross basis, which net of stock-based compensation —material at this company— arrives at the same place. The longer window corroborates the direction and shows the pace decelerating —−5.6% between fiscal 2024 and 2025, against −2.4% over the trailing twelve months—, and §6 mandates anchoring on the twelve-month window precisely because the longer one describes behavior that has already changed.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $1,093 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $852, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $1,093 in 5 years plus $23 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $897. Against the current market price ($852), the margin of safety is 5.0% (trades below the maximum → there is margin) and the total return at that price would be 5.6% annually.

• Entry multiple near the top of the band. The entry EV/NOPAT (~22×) on trailing-twelve-month after-tax operating income sits near the top of the pharmaceutical band [14×,22×], reflecting the business's still-elevated growth.
• Multiple compression toward the terminal. The base case's exit multiple (17×) compresses versus the entry multiple, consistent with the projected growth deceleration toward year 5.
• Relevant net cash in the bridge. The net cash position (~$15.8 billion) represents close to 17% of the current market value and is added in full to enterprise value in the bridge to equity.
• Sustained material buybacks. The net reduction in diluted shares (~4%-5% annually over recent fiscal years) is modeled as a single share path across the three scenarios, increasing per-share value without relying on multiple expansion.
• Price near the 52-week high. The stock trades near its 52-week high ($555.51-$852.03), reducing the available margin of safety against an operational or regulatory stumble.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (116%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on capital. 20.8%, well above the 10% bar, supported by a low-capital collaboration model and manufacturing scale already built; the incremental figure is omitted for lack of a reliable multi-year invested-capital series.
• Cash conversion. Trailing-twelve-month operating cash flow ($4,681.3M) comfortably exceeds capex ($920.9M), though capex is growing faster than depreciation —investment mode— from the manufacturing expansion at Tarrytown and Saratoga Springs.
• Material stock-based compensation. Stock-based compensation expense (26.2% of trailing-twelve-month free cash flow, 6.4% of revenue) is material against the flow; the valuation metric (EV/NOPAT) already expenses it, being calculated on GAAP operating income.
• Margins under pressure. The consolidated operating margin fell from 30.9% (2023) to 24.7% (trailing twelve months), from the expansion of research and development, higher inventory reserves, and intangible amortization tied to Libtayo royalties.
• Net income with non-operating noise. Trailing-twelve-month net income includes significant gains on marketable securities ($946.1M in 2025) that are not part of the operating business; the valuation relies on operating income, not on reported net income.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Regeneron does not report traditional operating segments: revenue is split by type (own product sales vs. collaboration revenue) and by product within each type. Today's most informative driver is not geographic but the transition between legacy EYLEA (in structural decline from biosimilars) and EYLEA HD (still in volume expansion), together with collaboration revenue from Sanofi and Bayer, which has already surpassed net product sales in dollars and is the largest revenue source. The full repayment of Sanofi's development balance at the end of the second quarter of 2026 removes a recurring deduction from that line starting in the third quarter onward.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• EYLEA HD only partly offsets EYLEA. EYLEA HD +36% ($1,636.9M in 2025) does not fully offset legacy EYLEA's decline (−42%, roughly −$2,020M); the combined franchise is down in dollars.
• Collaboration as the main engine. Collaboration revenue (+21% year over year in 2025) already exceeds own-product revenue and is the main consolidated growth engine.
• Repayment of Sanofi's balance unlocks growth. Sanofi's development balance was fully repaid by the end of the second quarter of 2026, eliminating a recurring deduction from collaboration revenue.
• Libtayo with high double-digit growth. Libtayo global sales +30% year over year in the second quarter of 2026, with expansion both in the United States and abroad.
• Reacceleration of total revenue. Consolidated growth went from 1.0% in 2025 to 9.3% over the trailing twelve months through June 2026; the second quarter alone grew 17%.

• Single segment, no breakdown by parts. Regeneron operates and reports as a single discovery, development, and commercialization segment; there is no financial or real-estate piece warranting sum-of-the-parts valuation.
• Dependence on three franchises. EYLEA HD/EYLEA and the collaboration with Sanofi (mostly Dupixent) concentrate most of the revenue; a single franchise in structural decline (EYLEA) already weighs on the consolidated business.
• Customer concentration. Two distributors accounted for 77% of gross product revenue in 2025, a concentrated counterparty risk though typical of the U.S. pharmaceutical channel.
• Low-capital collaboration model. The collaborations with Sanofi and Bayer allow global commercial scale without building a full proprietary sales force in every market, improving return on capital.
• Broad, diversified pipeline. Close to 50 candidates in clinical development reduce dependence on any single launch, though none yet replaces the scale of EYLEA or Dupixent.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $15.8 bn
• ✓Interest coverage (EBIT / interest)87.6x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 116% of ROIC
• ✓Value creation (ROIC − 10% bar)+11pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 1.7x
• ✓Float / working capitalFrees up cash $0.5 bn (float / negative WC)
• !Dilution (SBC % of revenue + shares)SBC 6.4% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Minimal, long-term debt. The only debt is 1.75% senior notes due 2030, ~$2.0 billion; there is no current debt or short-term maturities generating refinancing pressure.
• Broad cash and marketable securities position. Close to $17.8 billion between cash, and current and non-current marketable securities as of the close of the second quarter of 2026 — a net cash position that alone funds the declared buyback and dividend.
• Accounts receivable concentration. Two distributor customers accounted for 87% of net product accounts receivable in 2025, a concentrated counterparty risk in the pharmaceutical distribution channel.
• Ample interest coverage. Interest expense (~$44 million annually) is marginal against trailing-twelve-month operating income ($3,843.1 million) — interest coverage is not a business constraint.
• Regulatory and litigation contingency. The ongoing litigation with the Department of Justice and the Massachusetts Attorney General, plus the litigation with Sanofi over the Dupixent collaboration, are contingent liabilities whose outcome the company states it cannot quantify.

• Founder leadership. Leonard S. Schleifer, co-founder of the company in 1988, is Chairman of the Board (co-Chair), President, and Chief Executive Officer — more than three decades of continuity leading the business.
• Dual-class share structure. Common Stock and Class A Stock coexist, with Class A typically concentrating voting control in the founders' hands; the quantitative ownership detail remains pending from the DEF 14A proxy.
• Capital allocation toward buybacks and dividend. $2.0 billion repurchased in the first half of 2026 and the first cash dividend paid in 2025 ($370.3M), with an ongoing buyback program for an additional $2.5 billion.
• Investment in own manufacturing. The construction of the Saratoga Springs plant and the Tarrytown expansion aim to reduce dependence on third-party manufacturing, following Catalent's failures in 2025.

• The market discounts the structural erosion of EYLEA (biosimilars and loss of copay assistance), already reflected in the 42% decline of that historical line
• The litigation with Sanofi over access to Dupixent collaboration information introduces unquantifiable uncertainty over the franchise that is already 41% of revenue
• Third-party manufacturing failures (Catalent) in 2025 delayed key approvals, evidencing operational fragility

There is no clear source of missing buyers or motivated sellers: the stock trades near its 52-week high after two consecutive quarters of double-digit growth. The price already incorporates the repayment of Sanofi's balance and the strength of Libtayo/EYLEA HD; what is not fully discounted is how much EYLEA's erosion accelerates against the new biosimilars.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -6%/year (-25% total): the margin of safety protects the downside. The bull (+12%/year, +77% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Structural erosion of EYLEA from biosimilars and loss of copay assistance. EYLEA sales in the United States fell 42% year over year in 2025; more biosimilars are expected in the second half of 2026, and the company states that the magnitude and duration of this impact is currently unknown.
• Critical dependence on third-party manufacturing. The FDA inspection at Catalent's (Novo Nordisk) plant that fills EYLEA HD resulted in a complete response letter in October 2025, delaying approval of the prefilled syringe and of odronextamab.
• Litigation with Sanofi over the Dupixent collaboration. Regeneron sued Sanofi for breach of information-access and audit obligations under the collaboration agreement; the company states it cannot determine the impact on the commercial relationship.
• U.S. regulatory pricing pressure. Medicare price negotiation under the Inflation Reduction Act reaches Part B drugs (which covers EYLEA HD and EYLEA) starting in 2028, and the government requested most-favored-nation pricing for Medicaid in July 2026.
• Growing competition from Chinese biotechnology companies. The filing states that China became one of the world's leading developers of new drugs, with a regulatory regime that allows faster and cheaper clinical trials — it already led Regeneron to license a Chinese GLP-1/GIP asset from Hansoh.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 8% at a multiple/growth of 3.0 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 5% (EBIT/EV) + ROIC 21% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -3% vs our 8%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -6%/yr, bull-scenario ceiling +12%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, efficient scale, switching costs, cost advantage → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -3%, within what we project (8%) — the story squares with the numbers.